Neil S. Belloff
General Counsel bei ACORDA THERAPEUTICS, INC.
Vermögen: - $ am 31.03.2024
Profil
Neil S.
Belloff is currently the Secretary & General Counsel at Acorda Therapeutics, Inc. He previously worked as the Senior Corporate Counsel at Celgene Corp.
and as the Executive VP, US Corporate & Securities Counsel at Deutsche Telekom AG.
From 2020 to 2021, he served as the COO, Secretary, EVP & General Counsel at Eloxx Pharmaceuticals, Inc. Mr. Belloff completed his undergraduate studies at Queens College and his graduate studies at New York University.
He also obtained a graduate degree from Quinnipiac University School of Law.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.04.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Neil S. Belloff
| Unternehmen | Position | Beginn |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | General Counsel | 08.11.2021 |
Ehemalige bekannte Positionen von Neil S. Belloff
| Unternehmen | Position | Ende |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Chief Operating Officer | 25.08.2021 |
| CELGENE | Corporate Officer/Principal | - |
| DEUTSCHE TELEKOM AG | Corporate Officer/Principal | - |
Ausbildung von Neil S. Belloff
| Queens College | Undergraduate Degree |
| New York University | Graduate Degree |
| Quinnipiac University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| DEUTSCHE TELEKOM AG | Communications |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
